Outlook Therapeutics (OTLK) Net Cash Flow (2015 - 2026)
Outlook Therapeutics (OTLK) reported Net Cash Flow of -$929198.0 for Q1 2026, down 150.13% year-over-year from $1.9 million in Q1 2025, and down 256.34% quarter-over-quarter from $594339.0 in Q4 2025.
Outlook Therapeutics (OTLK) Net Cash Flow (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Net Cash Flow data on file, last reported at -$929198.0 in Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$929198.0, down 150.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $191913.0 (up 100.48% YoY), and the FY2025 annual result was -$6.8 million, up 19.14% from the prior year.
- Net Cash Flow eased to -$929198.0 in Q1 2026 per OTLK's latest filing, from $594339.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $36.9 million in Q1 2024 and troughed at -$32.4 million in Q2 2022.
- A 5-year average of -$3.7 million and a median of -$8.7 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow jumped 523.25% in 2024, then tumbled 150.13% in 2026.
- A 5-year view of Net Cash Flow shows it stood at $34.9 million in 2022, then slumped by 137.3% to -$13.0 million in 2023, then grew by 29.23% to -$9.2 million in 2024, then jumped by 106.44% to $594339.0 in 2025, then slumped by 256.34% to -$929198.0 in 2026.
- Business Quant data shows OTLK's Net Cash Flow at -$929198.0 in Q1 2026, $594339.0 in Q4 2025, and -$817729.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 664,983.53 |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | -929,198.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -929,198.00 |
| Mar 31, 2026 | -929,198.00 |
| Dec 31, 2025 | 594,339.00 |
| Dec 31, 2025 | 594,339.00 |
| Sep 30, 2025 | -817,729.00 |
| Sep 30, 2025 | -817,729.00 |
| Jun 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | -9.22 Mn |
| Dec 31, 2024 | -9.22 Mn |
| Sep 30, 2024 | -17.10 Mn |
| Sep 30, 2024 | -17.10 Mn |
| Jun 30, 2024 | -15.20 Mn |
| Jun 30, 2024 | -15.20 Mn |
| Mar 31, 2024 | 36.87 Mn |
| Mar 31, 2024 | 36.87 Mn |
| Dec 31, 2023 | -13.04 Mn |
| Dec 31, 2023 | -13.04 Mn |